Celldex Therapeutics
CLDX
140 hedge funds and large institutions have $293M invested in Celldex Therapeutics in 2016 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 47 increasing their positions, 42 reducing their positions, and 15 closing their positions.
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
12% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 42
4.56% more ownership
Funds ownership: 0% → 4.56% (+4.6%)
1% more funds holding
Funds holding: 138 → 140 (+2)
4% more capital invested
Capital invested by funds: $281M → $293M (+$11.2M)
2% more call options, than puts
Call options by funds: $1.88M | Put options by funds: $1.85M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.1M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$12.5M |
| 3 |
DM
Deerfield Management
New York
|
+$2.4M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.1M |
| 5 |
QI
QS Investors
New York
|
+$1.57M |
Top Sellers
| 1 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$4.02M |
| 2 |
RI
RTW Investments
New York
|
-$3.81M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$3.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.95M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.53M |
CLDX Hedge Fund Activity: Q4 2016 in Review
140 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2016, worth a combined $293M — up 4% from $281M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CLDX positions and 15 closed out — a net gain of 3 holders — while 47 added to existing stakes and 42 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $21.1M. The largest seller was Bogle Investment Management, exiting entirely with an estimated $4.02M sold.
- 140 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2016, up from 138 in Q3 2016.
- Funds reported $293M of Celldex Therapeutics stock for Q4 2016, up 4% quarter-over-quarter.
- 18 funds opened new Celldex Therapeutics positions in Q4 2016 and 15 closed out, a net change of +3 holders.
- The largest Celldex Therapeutics buyer in Q4 2016 was Fidelity Investments, an estimated $21.1M added.
- The largest Celldex Therapeutics seller in Q4 2016 was Bogle Investment Management, an estimated $4.02M sold.
Based on aggregated 13F filings for Q4 2016.